Showing 21 - 40 results of 33,254 for search '(( 50 ((n decrease) OR (nn decrease)) ) OR ( 5 ((ng decrease) OR (we decrease)) ))', query time: 0.53s Refine Results
  1. 21

    Expanding Three-Coordinate Gold(I) Anticancer Agent Chemical Space by Charles E. Greif (21728091)

    Published 2025
    “…The complexes demonstrated submicromolar cytotoxic activity against human breast cancer cells MDA-MB-231 or MDA-MB-468 with IC<sub>50</sub>’s in the range of 0.4–5.0 μM. Complex <b>2e</b> shows high potency in vitro and decreases 3D-breast cancer mammosphere viability. …”
  2. 22
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27

    Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d’Ivoire: A model-based analysis by Eric N. Ouattara (6890174)

    Published 2019
    “…Outcomes from the model included life expectancy, 10-year medical resource use, incremental cost-effectiveness ratios (ICERs) in $/year of life saved (YLS), and 5-year budget impact. We simulated people with HIV (PWH) in care (mean CD4: 259/<i>μ</i>L, SD 198/<i>μ</i>L) and transmitted cases. …”
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33

    NgR1 KO mice exhibited an increase in excitatory synapses and a decrease in inhibitory synapses, indicating an imbalance of synaptic transmission. by Jinwei Zhang (462455)

    Published 2025
    “…The inhibitory synaptic density of NgR1 mice showed a significant decrease when compared to WT mice (***P <  0.001). …”
  14. 34

    Data_Sheet_1_Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020–May 2021).PDF by Inés Barbeito (5864351)

    Published 2023
    “…</p>Methods<p>A stringency index (0–1) was created for each Spanish province (n = 50) daily. A hierarchical multiplicative model was fitted. …”
  15. 35
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40

    S1 Data - by Francois Kiemde (5369657)

    Published 2024
    “…Venous blood was collected at scheduled visit: Visit 1 (V1; 16–20 weeks of amenorrhea), Visit 2 (V2; 28 ±1 weeks of pregnancy), Visit 3 (V3; 32 ±1 weeks of pregnancy), Visit4 (V4; delivery) and Visit5 (V5; 6–7 weeks after delivery). …”